

Thierry Lesimple

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3046783/publications.pdf>

Version: 2024-02-01

11
papers

2,311
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

3053
citing authors

#	ARTICLE	IF	CITATIONS
1	The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	10
2	MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. <i>European Journal of Cancer</i> , 2022, 173, 105-112.	2.8	17
3	Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010â€“2017. <i>Journal of Investigative Dermatology</i> , 2021, 141, 830-839.e3.	0.7	10
4	Phase lâ€“II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i>V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. <i>Clinical Cancer Research</i> , 2021, 27, 3876-3883.	7.0	8
5	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	3.7	3
6	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	27.0	256
7	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
8	Reply to E. HindiÃ© and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	1.6	1
9	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i>V600â€“Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	1.6	226
10	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
11	Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	27.0	1,192